Holen Sie sich die Stockscreener-App
11.51
15.24%
-2.07
Handel nachbörslich:
12.18
0.67
+5.82%
Schlusskurs vom Vortag:
$13.58
Offen:
$12.67
24-Stunden-Volumen:
4.45M
Relative Volume:
2.95
Marktkapitalisierung:
$1.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-115.88M
KGV:
-7.4412
EPS:
-1.5468
Netto-Cashflow:
$-104.72M
1W Leistung:
-50.54%
1M Leistung:
-53.02%
6M Leistung:
-59.47%
1J Leistung:
-30.33%
1-Tages-Spanne:
$11.50
$13.28
1-Wochen-Bereich:
$11.50
$23.12
52-Wochen-Spanne:
$11.50
$38.12
Edgewise Therapeutics Inc Stock (EWTX) Company Profile
Firmenname
Edgewise Therapeutics Inc
Sektor
Branche
Telefon
720-262-7002
Adresse
1715 38TH ST, BOULDER
Vergleichen Sie EWTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EWTX
Edgewise Therapeutics Inc
|
11.51 | 1.10B | 0 | -115.88M | -104.72M | -1.5468 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Edgewise Therapeutics Inc Stock (EWTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-01-22 | Eingeleitet | Stifel | Hold |
| 2024-11-22 | Eingeleitet | Evercore ISI | Outperform |
| 2024-03-07 | Eingeleitet | Piper Sandler | Overweight |
| 2023-05-01 | Eingeleitet | Truist | Buy |
| 2022-08-25 | Herabstufung | Goldman | Neutral → Sell |
| 2022-04-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-01-28 | Eingeleitet | Goldman | Neutral |
Alle ansehen
Edgewise Therapeutics Inc Aktie (EWTX) Neueste Nachrichten
Edgewise Therapeutics director Peter Thompson acquires $10 million in stock - Investing.com
OrbiMed Advisors LLC purchases $10 million in Edgewise Therapeutics stock - Investing.com
Piper Sandler Reiterates Overweight Rating for Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Lowered to Sector Perform Rating by Scotiabank - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Rating Lowered to "Sector Perform" at Scotiabank - MarketBeat
Investors Buy High Volume of Put Options on Edgewise Therapeutics (NASDAQ:EWTX) - MarketBeat
Edgewise Therapeutics (NASDAQ:EWTX) Hits New 12-Month LowShould You Sell? - MarketBeat
Edgewise Therapeutics falls after pricing $200M offering - MSN
Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial - GuruFocus
Edgewise Therapeutics (NASDAQ:EWTX) Shares Down 7.3%Should You Sell? - MarketBeat
Edgewise Therapeutics Says Believes Atrial Fibrillation Not Driven by EDG-7500 in Phase 2 Trial, RBC Says - MarketScreener
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Shares Sold by American Century Companies Inc. - MarketBeat
Edgewise Therapeutics downgraded at Scotiabank on heart disease trial results - Seeking Alpha
Edgewise shares slide amid trial and stock news - The Pharma Letter
RBC Capital cuts Edgewise Therapeutics target to $52 By Investing.com - Investing.com Canada
Edgewise’s HCM Candidate May Provide Advantages Over BMS’s Camzyos - insights.citeline.com
Edgewise Therapeutics selling $200M in stock to support drug commercialization - BizWest
Edgewise down on atrial fibrillation; cardiomyopathy data positive - BioWorld MedTech
Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (EWTX) - Seeking Alpha
Why These Two Biotech Stocks Just Diverged - Investor's Business Daily
Edgewise Therapeutics sets $20.13 share price in $200 million stock offering By Investing.com - Investing.com South Africa
Edgewise reports promising HCM trial results for EDG-7500 By Investing.com - Investing.com South Africa
Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' - Investopedia
CYTK Gains as EWTX Data and Fundraising Impact Stock Movement - GuruFocus
Edgewise stock holds Buy rating, $50 target from Truist Securities By Investing.com - Investing.com UK
Edgewise Therapeutics Sees Meaningful HCM Treatment Gains With EDG-7500 In Phase 2 Study - Benzinga
Why Edgewise Therapeutics (EWTX) Stock Is Falling - Benzinga
Edgewise falls on safety, efficacy doubts for heart disease drug - TradingView
Cytokinetics stock rises on Edgewise data for lead drug (EWTX) - Seeking Alpha
Edgewise Therapeutics stock tumbles after trial results and stock offering By Investing.com - Investing.com Australia
Edgewise Therapeutics stock tumbles after trial results and stock offering - Investing.com India
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) - BioSpace
Edgewise Therapeutics sets $20.13 share price in $200 million stock offering - Investing.com Australia
Edgewise Therapeutics Prices 9.9 Mln Offering At $20.13/shr; Stock Fell In Pre-market - Nasdaq
Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 Cirrus-Hcm Four-Week Trial of Edg-7500 in Hypertrophic Cardiomyopathy - MarketScreener
Edgewise’s heart drug shows promise in Phase 2 trial - Endpoints News
Edgewise Therapeutics Reports New Results From Phase 2 Hypertrophic Cardiomyopathy Trial - MarketScreener
Edgewise reports promising HCM trial results for EDG-7500 - Investing.com India
Edgewise Therapeutics Prices $200 Million Offering - MarketScreener
Edgewise Therapeutics Announces Positive Phase 2 Trial Results - TipRanks
Edgewise Therapeutics announces top-line data of EDG-7500 from CIRRUS-HCM trial - TipRanks
Why Edgewise Therapeutics Is Rising In Pre-market? - Nasdaq
$200M Funding Positions Edgewise to Launch Breakthrough Muscular Dystrophy Treatment - Stock Titan
Edgewise Therapeutics Announces Positive Top-Line Results From Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy - MarketScreener
Teacher Retirement System of Texas Buys 1,772 Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Artisan Partners Limited Partnership Increases Stock Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Hypertrophic Cardiomyopathy Market to Show Remarkable Growth - openPR.com
Quantbot Technologies LP Invests $103,000 in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - Defense World
Edgewise Therapeutics (NASDAQ:EWTX) Trading Up 9.3%Still a Buy? - MarketBeat
EFG Asset Management North America Corp. Acquires New Holdings in Edgewise Therapeutics, Inc. (NASDAQ:EWTX) - MarketBeat
Brokerages Set Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Price Target at $45.38 - MarketBeat
Finanzdaten der Edgewise Therapeutics Inc-Aktie (EWTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):